TABLE 1.
Characteristics of included studies.
| References | Center | Type of study | Registration | Duration of treatment | Number of patients enrolled | Number of patients underwent teduglutide |
| Carter et al. (18) | Multicenter study at 17 sites in the US and the United Kingdom | Prospective | ClinicalTrials.gov: NCT01952080 | 12 weeks | 42 | 37 |
| Busoni et al. (19) | One reference IF center in Latin America | Retrospective | 22 months | 3 | 3 | |
| Ferreiro et al. (20) | Single center in Spain | Case report | 60 weeks | 1 | 1 | |
| Hill et al. (22) | U | Prospective |
ClinicalTrials.gov: NCT02949362 |
6 months | 16 | 16 |
| Kinberg (23) | Single center in US | Retrospective | 10 months (3–18)x | 8 | 8 | |
| Lambe (25) | Single center in France | Prospective | ClinicalTrials.gov: NCT03562130 | 48 weeks | 25 | 25 |
| Kocoshis et al. (24) | Multicenter in 24 centers in North America and Europe | Prospective | ClinicalTrials.gov, NCT02682381 | 24 weeks | 59 | 50 |
| Martìnez et al. (26) | Single center in Argentina | Retrospective | 42 weeks ± 42.5 weeksy | 4 | 4 | |
| Ramos-Boluda et al. (16) | Multicenter study at 8 sites in Spain | Prospective | 12 months | 17 | 17 | |
| Ribeiro-Mourão et al. (15) | Single center in Portugal | Prospective | 6 months | 4 | 4 | |
| Rumbo et al. (17) | Single center in Argentina | Case report | 50 weeks | 1 | 1 | |
| Sigalet et al. (9) | Two sites in Canada | Prospective | ClinicalTrials.gov: NCT01573286 | 42 days | 7 | 7 |
| Sigalet et al. (12) | Three sites in Canada | Prospective | ClinicalTrials.gov: NCT01573286 | 42 days | 6 | 6 |
| Mercer et al. (21) | U | Prospective | ClinicalTrials.gov: NCT02954458 | 6 months |
55 | 44 |
| Total | 248 | 223 |
U, unknown; xMedian duration and range, yMean duration and standard deviation.